Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities

Cakmak R., Caklili O. T., Tekin S., Hacisahinogullari H., Tanrikulu S., Koc M. S., ...Daha Fazla

BIOMARKERS IN MEDICINE, cilt.16, ss.5-10, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/bmm-2021-0318
  • Dergi Adı: BIOMARKERS IN MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.5-10
  • İstanbul Üniversitesi Adresli: Evet

Özet

Aim: Study aims to assess amylase, lipase of patients with Type 2 diabetes under different types of treatments. Materials & methods: Patients' treatment modalities including insulin, metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors, insulin secretagogues, dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists were compared. Results: There was no difference in amylase and lipase levels between dipeptidyl peptidase-4 inhibitor users and non-users (p = 0.2, p = 0.3, respectively) and glucagon like peptide-1 analog users and non-users (p = 0.1, p = 0.7, respectively). Patients who use insulin secretagogues had significantly higher amylase, lipase and (77.2 +/- 39.8 vs 69.5 +/- 33.0, p = 0,038 and 47.2 +/- 33.2 vs 39.6 +/- 26.8, p = 0.01, respectively) patients on basal insulin had lower amylase levels (69.9 +/- 37.7 vs 77.2 +/- 33.7, p = 0.014). Conclusion: Incretin-based therapies showed no difference in amylase and lipase levels whereas there was increase with secretagogues and decrease with basal insulin.